ProJenX

Amyotrophic lateral sclerosis, or ALS, is a progressive disease that kills motor neurons - the nerve cells that carry signals from the brain to the muscles. As those neurons die, people lose the ability to move, speak, swallow, and eventually breathe. There is no cure, and the causes are many. That last fact is the hard part: ALS is not one disease but many roads to the same destination.

ProJenX's answer was to stop chasing the many causes and target the shared endpoint instead. Its scientific co-founders at Columbia discovered that inhibiting a family of enzymes called MAP4 kinases protected motor neurons across multiple patient stem cell-derived models of ALS - regardless of the underlying genetic cause. That observation became the whole thesis of the company.

From that finding, the team optimized a molecule - prosetin - for three things at once: potency against MAP4Ks, the ability to rescue motor neurons, and preferential distribution into the central nervous system. The result is what ProJenX describes as the first brain-penetrant MAP4K inhibitor therapy to enter clinical trials.

Behind it sits a lean operation. ProJenX has around nine employees, a Series A of $15 million that closed in November 2023, and a total of roughly $21 million raised including seed capital and non-dilutive grants. It is a reminder that a serious drug program does not require a large team - it requires a target worth chasing and the focus to pursue it.

The model. ProJenX is a clinical-stage biotech funded by venture capital, a founding investor, and disease-focused grants. It develops a proprietary drug candidate through trials toward potential approval or partnership. It does not yet generate revenue; it runs on raised capital and non-dilutive awards such as the ALS Association's $1M Hoffman award.

Who it serves. The ultimate customers are people living with ALS - and potentially patients with other neurodegenerative brain diseases. Near-term stakeholders include trial participants, neurologists and ALS treatment centers, the patient-advocacy community, and prospective biopharma partners.

The market. ALS drug development is a competitive, high-risk field. ProJenX sits among companies and programs such as Amylyx, Denali Therapeutics, QurAlis, Clene, Verge Genomics, and Biogen's tofersen - alongside academic ALS research. Its differentiator is the specific mechanism and brain-penetrant design of prosetin.

The expertise. The team blends translational neuroscience from Columbia University with the patient insight of Project ALS and the operating experience of CEO Stan Abel, a life-sciences veteran who has raised more than $100 million across prior emerging biotech companies.